Sarepta Accused Of Misleading Investors On MD Drug

Law360, New York (January 28, 2014, 4:56 PM EST) -- A Sarepta Pharmaceuticals Inc. shareholder filed a class action against the company in Massachusetts federal court Monday, alleging it intentionally misled investors about muscular dystrophy drug eteplirsen's chances of hitting the open market.

Mark A. Corban claims that he and potentially thousands of others who bought or sold securities in Sarepta between July 24 and Nov. 12, 2013, based their decisions on incomplete or deceiving information the company had provided about eteplirsen, Sarepta's leading candidate for production.

“Had plaintiff and the other members of the class...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Corban v. Sarepta Therapeutics, Inc. et al


Case Number

1:14-cv-10201

Court

Massachusetts

Nature of Suit

Securities/Commodities

Judge

Indira Talwani

Date Filed

January 27, 2014

Law Firms

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.